Home・Akciju saraksts・Editas Medicine Inc

Editas Medicine Inc

Slēgts

SektorsVeselības aprūpe

2.87

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.81

Max

3.02

Galvenie mērījumi
By Trading Economics
Ienākumi	6.8M -18M
Pārdošana	9.1M 12M
EPS	-0.15
Peļņas marža	-153.322
Darbinieki	87
EBITDA	3.9M -20M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+171.19% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 9. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	25M 432M
Iepriekšējā atvēršanas cena	2.87
Iepriekšējā slēgšanas cena	2.87

Ziņu noskaņojums

By Acuity

63%

37%

279 / 340 Rangs Healthcare

Editas Medicine Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. aug. 19:46 UTC

Editas Medicine Inc shares are trading higher today, reflecting unusual strength. No specific company news was identified to explain this price action.

2026. g. 10. aug. 23:26 UTC

Editas Medicine Inc shares are higher in after-market hours. No specific company news was identified to explain this movement amid broader market uncertainties.

2026. g. 7. aug. 23:16 UTC

Editas Medicine Inc. shares were little changed in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

2026. g. 6. aug. 23:02 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum following a strong trading session despite no specific company news.

2026. g. 5. aug. 22:02 UTC

News

Editas Medicine reports second-quarter loss of $18.2 million, better than expected. Shares are higher after positive updates on EDIT-401 program and revenue growth.

2026. g. 31. jūl. 19:56 UTC

Correlated Moves

EDIT shares lower amid broader biotech sector decline today.

2026. g. 30. jūl. 23:51 UTC

Editas Medicine Inc shares are lower in after-market trading, continuing a decline since Thursday's close while remaining near the lower end of its one-month range.

2026. g. 29. jūl. 23:46 UTC

Editas Medicine Inc shares are lower in after-market hours, with no specific news identified. The stock remains near its one-month low amid broader market caution.

2026. g. 28. jūl. 20:07 UTC

Editas Medicine Inc shares are trading lower today, continuing a broader trend in the biotechnology sector. The stock remains below its 20-day moving average.

2026. g. 27. jūl. 17:26 UTC

Editas Medicine Inc is trading higher today, following a notable peak. The upward movement comes amid easing inflation concerns from declining oil prices.

2026. g. 24. jūl. 17:46 UTC

Editas Medicine Inc shares are lower today, continuing a trend of declines over the past three sessions amid broader market volatility linked to falling oil prices.

2026. g. 22. jūl. 19:26 UTC

Editas Medicine Inc is lower today, continuing a decline since Tuesday's close. Broader market weakness may be influencing investor sentiment.

2026. g. 21. jūl. 23:11 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum since Tuesday's close, though they remain below their 20-day moving average.

Salīdzinājums

Cenas izmaiņa

Editas Medicine Inc Prognoze

Cenas mērķis

By TipRanks

171.19% augšup

Prognoze 12 mēnešiem

Vidējais 8 USD 171.19%

Augstākais 15 USD

Zemākais 4 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Editas Medicine Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Editas Medicine Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

279 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.